Biopharmaceutical News and Research

RSS

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Sanofi notified Ardelyx of its termination of the option and license agreement for Ardelyx's portfolio of NaP2b inhibitors effective September 30, 2015.

2 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Practices for expediting corporate market research approval process for faster insights

Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. It is, therefore, absolutely critical for biopharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.

29 Aug 2015

CytomX announces filing of registration statement for proposed initial public offering of common stock

CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

29 Aug 2015

Breakthrough approach saves patient's eyes and life from flesh-eating disease

The National Necrotizing Fasciitis Foundation today announced that a patient's eyes—and life—were saved by doctors at Vanderbilt University Hospital in Nashville, TN, working with NNFF, NovaBay Pharmaceuticals and Dr. John Crew, director of the Advanced Wound Care Center at Seton Medical Center in Daly City, CA.

27 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

MNX Global Logistics' new Life Sciences Logistics Centre opens in Amsterdam

MNX Global Logistics announces the opening of its dedicated supply chain and logistics facility in Amsterdam, the Netherlands, located just outside of Amsterdam Airport Schiphol. This facility with validated temperature-controlled supply chain capabilities will serve as the operations and warehousing hub for our Life Sciences and Medical Device customers throughout Europe.

25 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030.

23 Aug 2015

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

caprotec bioanalytics GmbH announced today that the United States Patent Office has issued patent No. US9,034,789 covering its revolutionary Capture Compound Mass Spectrometry (CCMS) technology.

20 Aug 2015

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax.

19 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

CASI reports financial results for second quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and six months ended June 30, 2015.

14 Aug 2015

RealTime Dynamix: New monthly service launched for pharmaceutical markets

Spherix Global Insights announces the launch of RealTime Dynamix, its new monthly service developed to keep clients on the pulse in highly dynamic specialty markets.

13 Aug 2015

Biopharmaceutical News and Research

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Practices for expediting corporate market research approval process for faster insights

CytomX announces filing of registration statement for proposed initial public offering of common stock

Breakthrough approach saves patient's eyes and life from flesh-eating disease

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

MNX Global Logistics' new Life Sciences Logistics Centre opens in Amsterdam

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

DelMar closes on $2.6 million registered direct placement

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

CASI reports financial results for second quarter 2015

RealTime Dynamix: New monthly service launched for pharmaceutical markets

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News